Skip to content
Research Article Open access CC BY 3.0

Metabolic Characterization and Follow up of Adult Patients Affected by Osteogenesis Imperfecta in Long-term Treatment with Neridronic Acid

Rachele Fornari, Paolo Sgro, Emanuela Greco, Davide Francomano, Antonio Aversa, Mario Marini, Carla Lubrano, Chiara Marocco, Francesco Conti, Giovanni Spera, Luigi Di Luigi, Andrea Lenzi, Silvia Migliaccio

Journal of Advances in Medicine and Medical Research · pp. 478–485 · Published 22 Sep 2011

10.9734/BJMMR/2011/501

Abstract

Aims: Osteogenesis imperfecta (OI) is a rare inherited disorder causing low bone density and increased fragility. Bisphosphonates (BP) are a treatment of choice for OI. Few studies have investigated the long-term effects of BP in OI patients. Thus, aim of our study was to follow up adults affected by OI to evaluate changes in metabolic, clinical situation and safety of long-term neridronic acid therapy, BP authorized for OI treatment. Study design: Longitudinal observational study. Place and duration of the Study: Department of Experimental Medicine, Section of Medical Pathophysiology, Endocrinology and Nutrition. Year: 2004 - October 2010. Methodology: 68 patients underwent clinical examination, laboratory endocrine/ metabolic, pro-inflammatory cytokines screening, ECG at baseline and every 3 months and bone mineral density evaluation, by DEXA, once a year. Results: Skeletal evaluation showed a significant increase of BMD through follow up. Patients were evaluated for metabolic and cardiovascular risk factors, which were unmodified by long-term therapy. Conclusion: Long-term neridronic acid treatment increases bone density, does not alter metabolic parameters indicating that this therapy can be considered safe and a valid therapeutic option for OI patients.

Osteogenesis imperfect metabolic markers skeletal markers neridronic acid BMD

References (13)

  1. 1 Bisphosphonates: Mechanism of Action and Role in Clinical Practice [DOI]
  2. 2 Bisphosphonate therapy for osteogenesis imperfecta [DOI]
  3. 3 Osteogenesis Imperfecta: Update on presentation and management [DOI]
  4. 4 Effects of Intravenous Pamidronate Treatment in Infants With Osteogenesis Imperfecta: Clinical and Histomorphometric Outcome [DOI]
  5. 5 Intravenous Neridronate in Adults With Osteogenesis Imperfecta [DOI]
  6. 6 Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL1A1 and COL1A2.
  7. 7 Current and emerging treatments for the management of osteogenesis imperfecta [DOI]
  8. 8 Osteogenesis imperfecta and cardiovascular diseases [DOI]
  9. 9 Heritable disorders of connective tissue [DOI]
  10. 10 Bisphosphonate Therapy for Osteogenesis Imperfecta
  11. 11 Bone Mineral Density and Fracture Rate in Response to Intravenous and Oral Bisphosphonates in Adult Osteogenesis Imperfecta [DOI]
  12. 12 Impairment of diastolic function in adult patients affected by osteogenesis imperfecta clinically asymptomatic for cardiac disease: Casuality or causality? [DOI]
  13. 13 [Left ventricular rupture following aortic and mitral valve replacement in a patient with osteogenesis imperfecta: a case report].

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

28

Page views

0

PDF downloads

4

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.